weill co rnell medical college main interest of his laboratory involves the molecular and biological...

The Newsletter of the Department of Pathology and Laboratory Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Volume 20 • February 2014

Research Highlightsby David P. Hajjar, PhD

Giorgio Inghirami, MD is a

practicing hematopathologist,

who joined Weill Cornell Medical

College in September 2013, as a

Professor of Pathology and Lab-

oratory Medicine. He has worked

in the field of molecular biology for

the last 2O years, defining the role

and distribution of pathogenetic

defects among lymphoproliferative

disorders. Detection of any given abnormality is believed to

improve diagnostic accuracy, and helps to provide clinical-

proven stratification. Indeed, patient-specific genomic finger-

prints will appropriately predict clinical outcomes, pinpoint

patient selective targets and thus tailor therapies. Restricted

defects in individual leukemia/lymphoma patients provide

the means to efficiently assess Minimal Residual Disease

(MRD) burden and to appropriately adjust therapeutic

programs.

Professor Inghirami has contributed more than 160 peer-

reviewed publications, mostly in the area of lymphoma

research, to the medical and scientific literature. He has

underwritten several international patents and has been the

Principal Investigator of several NIH-NCI, EU and Italian

grants. He has also been part of a multicentric program

sponsored by the Italian Cancer Research Association (AIRC)

on “genetics-driven targeted management,” and, he is a

cofounder of The European T-Cell Lymphoma Study Group.

His laboratory has used a variety of techniques including

deep sequencing, Doplet PCR, qRT-PCR, high-density tissue

microarrays, SNP arrays, and expression of cDNA arrays and

shRNA lentiviral libraries. His group has gained experience

using gene knockdown strategies in a variety of in vitro

models, and they have generated several mouse models and

a large library of human Patient Derived Tumorgrafts from

primary T-cell lymphoma (PTCL), B-cell disorders and Non-

Small Lung Cancers (NSCLC). continued on page 2

Contents

Weill Cornell Medical College

Giorgio Inghirami, MD

Figure 1: Schematic representation of Patient DerivedTumorgraft (PDT) mouse propagation. Primary samplesare implanted in immunocompromised mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) and tumor growth is checkedover time. Successful engraftments are then propagatedover time. Each tumor is characterized using multipleplatforms. Representative samples for each PDT are alsocryopreserved in a viable state for future expansions.

1-2Research Highlights

3Focus

4Keynotes

6Pathology Faculty’s

Global Travels

8Resident’s Corner

10Faculty Publications

122014-2015 CME Conference Calendar

Newly Awarded Grants in Pathology

Figure 2: Validation strategy for Patient DerivedTumorgraft (PDT) models. To assess the genomic configu-ration of PDT and to define the precise relationship betweenprimary and serially propagated PDT, individual PDT arecharacterized with a battery of assays designed to identifycommon and/emerging genetic defects. These studiesdelineate the limits and potentiality of individual PDT andtheir hypothetical usage. A good correspondence betweenprimary and PDT allows the design and execution of co-clinical therapeutic tests and the prediction of clinicalresponses for any given patient’s sample. Stable modelsoffer the opportunity to screen new drugs and/or innovativecombination protocols and thus the selection of newstrategies for individual types of human cancers.

The main interest of his laboratory involves the

molecular and biological characterization of PTCL,

in particular, Anaplastic Large Cell Lymphoma

(ALCL). A major effort has been devoted to the

development of innovative in vitro and in vivo mod-

els to test new compounds and preclinical proto-

cols. His contributions to the understanding of the

molecular mechanisms leading to ALCL transfor-

mation has been published in Nature Medicine,1-3

the Journal of Clinical Oncology,4 the Journal of

Clinical Investigation,5 among other journals.

The development of a functional genomics labora-

tory and more recently of a h Patient-Derived Tumor

Graft mouse facility led to the discovery of the sev-

eral molecular mechanisms leading to Anaplastic

Lymphoma Kinase-driven lymphomagenesis and

to the discovery of targets which could be explored

as sensitive molecules for innovative tailored thera-

pies.BCL2A1, & ATIC, Moreover, the transcriptional charac-

terization of a large panel of PTCL has provided

novel insights to the origin of ALCL4 and a diagnostic

classifier for routine clinical analyses.7 Molecular

cytogenetic analyses have recently identified a

high-risk group of patients, supporting the rationale

for the implementation of tailored upfront therapy

for naive ALCL patients.8 The discovery that ALK

fusion proteins are effective onco-antigens for lym-

phoma vaccination has opened new avenues for

the treatment of all ALK+ neoplasms and the possi-

bility to overcome chemo - and TKi-resistant neo-

plasms.2 The patent rights on mouse models and

innovative vaccinations are shared with New York

University. Dr. Inghirami's group works closely with

European, North and South American groups,

including the European T-Cell Lymphoma Study

Group and the European Research Initiative groups

studying ALK-related malignancies.

Dr. Inghirami had been the Director of Molecular

Pathology and Hematopathology at New York

University and Director of Anatomic Pathology at

the University of Torino, Italy. He has worked as

Scientific Director of the Center of Experimental

Research and Medical Science (CeRMS) in Torino. He

has contributed to the development of a specific

Pathogen Free Unit and a Functional Genomic

Laboratory at the Molecular Biotechnology Center

of the University of Torino. He serves as a reviewer

for multiple publications including Nature, the New

England Journal of Medicine, PNAS, and Blood. He

is the recipient of both the Benjamin Castleman

Award by the United States and Canadian Academy

of Pathology recognizing his contributions to the

field of pathology and the Shannon Award from the

National Cancer Institute. ■

References1.Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami

G. The anaplastic lymphoma kinase in the

pathogenesis of cancer. Nat Rev Cancer. 2008

Jan;8 (1):11-23. PMID: 18097461.

2.Chiarle R, Martinengo C, Mastini C, Ambrogio C,

D'Escamard V, Forni G, Inghirami G. The

anaplastic lymphoma kinase is an effective

oncoantigen for lymphoma vaccination. Nat

Med. 2008 Jun;14 (6):676-80. PMID: 18469826.

3.Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A,

Raz R, Karras JG, Levy DE, Inghirami G. Stat3 is

required for ALK-mediated lymphomagenesis

and provides a possible therapeutic target. Nat

Med. 2005 Jun;11(6):623-9. PMID: 15895073.

4.Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso

V, Tamagno I, Fornari A, Martinoglio B, Medico E,

Zamò A, Facchetti F, Ponzoni M, Geissinger E,

Rosenwald A, Müller-Hermelink HK, De Wolf-

Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami

G. Gene expression profiling uncovers molecular

classifiers for the recognition of anaplastic

large-cell lymphoma within peripheral T-cell

neoplasms. J Clin Oncol. 2010 Mar

20;28(9):1583-90. PMID: 20159827.

5.Piva R, Pellegrino E, Mattioli M, Agnelli L,

Lombardi L, Boccalatte F, CostaG, Ruggeri BA,

Cheng M, Chiarle R, Palestro G, Neri A, Inghirami

G. Functional validation of the anaplastic

lymphoma kinase signature identifies CEBPB

and BCL2A1 as critical target genes. J Clin

Invest. 2006 Dec;116 (12):3171-82. PMID:

17111047.

6.Boccalatte FE, Voena C, Riganti C, Bosia A,

D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen

ON, Goss VL, Lee K, Nardone J, Rush J,

Polakiewicz RD, Comb MJ, Chiarle R, Inghirami

G. The enzymatic activity of 5-aminoimidazole-

4-carboxamide ribonucleotide formyl-

transferase/IMP cyclohydrolase is enhanced

by NPM-ALK: new insights in ALK-mediated

pathogenesis and the treatment of ALCL. Blood.

2009 Mar 19;113(12):2776-90. PMID: 18845790.

7.Agnelli L, Mereu E, Pellegrino E, Limongi T,

Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J,

Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F,

Inghirami G, Piva R; European T-Cell Lymphoma

Study Group. Identification of a 3-gene model

as a powerful diagnostic tool for the recognition

of ALK-negative anaplastic large-cell lymphoma.

Blood. 2012 Aug 9;120(6):1274-81. PMID:

22740451.

8.Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M,

Tabbò F, Piva R, Rancoita PM, Matolcsy A, Timar

B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA,

Beà S, Campo E, Bhagat G, Swerdlow SH,

Rosenwald A, Ponzoni M, Young KH, Piccaluga

PP, Dummer R, Pileri S, Zucca E, Inghirami G,

Bertoni F. PRDM1/BLIMP1 is commonly

inactivated in anaplastic large T-cell lymphoma.

Blood. 2013 Sep 4. PMID: 24004669.

Research Highlightscontinued

Promotionsin Pathology

Yashpal Agrawal, MD, PhDpromoted toProfessor of Clinical Pathologyand LaboratoryMedicine

Rhonda K. Yantiss, MDpromoted toProfessor of Pathology andLaboratory Medicine

Melissa Cushing, MDpromoted toAssociate Professor of Clinical Pathologyand LaboratoryMedicine

Congratulations to our Docs!

Listed in the June 24-July1, 2013 issue of New YorkMagazine in the BestDoctors 2013:

Syed A. Hoda, MD;Attilio Orazi, MD

Listed in the May 19,2013 issue of The NewYork Times Magazine inNew York Super Doctors:®

Daniel M. Knowles, MD;Cynthia M. Magro, MD;Attilio Orazi, MD

NewYork-Presbyterian Hospital/Weill Cornell Medical Center

2 www.cornellpathology.org

Dr. Helen Fernandes,Associate Professor of

Pathology and Laboratory

Medicine, received her PhD

at the Tata Memorial Center

at the University of Bombay

in her native India in 1980.

Dr. Fernandes joins us from

the University Hospital of

UMDNJ, where she served

as Scientific Director of Molecular Diagnostics. Dr.

Fernandes was actively engaged in developing

next-generation sequencing in that laboratory and

it served as the principle molecular diagnostic

laboratory for a range of clinical trials sponsored

by multiple pharmaceutical companies.

Dr. Fernandes’ success as a laboratorian led to her

active involvement in the Association for Molecular

Pathology. She became a member of the Board of

Directors of that organization in January 2009

and joined the Executive Counsel of that organiza-

tion in November 2012. She has served on the

Credentialing Committee of the American Board of

Clinical Chemistry since June 2011, and on the

Molecular Methods Committee of the Clinical

Laboratory Standards Institute since January 2009.

Her involvement in these organizations, especially

the Association of Molecular Pathology, in a leader-

ship capacity is indication of her reputation in the

field of Diagnostic Molecular Pathology. She

received the Meritorious Service Award from the

Association for Molecular Pathology in 2012 and

also the Outstanding Speaker Award from the

American Association of Clinical Chemists in 2008,

2011 and 2012.

Given her outstanding track record of success, her

outstanding national reputation in the field, commit-

ment to clinical research and education, we are

delighted Dr. Fernandes has joined us to facilitate

growing our molecular diagnostic capabilities in the

clinical laboratories.

Dr. Yen-Chun Liu, Assistant Professor of Pathologyand Laboratory Medicine, received her medical

degree from the National Taiwan University in 2002

and received her PhD from The Johns Hopkins

University 2009. Subsequently, she joined the

Anatomic Pathology Resid-

ency Training Program at the

National Institutes of Health

Clinical Center, completing

her training in 2011. She then

joined our Hematopathology

Fellowship program followed

by a Molecular Pathology

Fellowship at MSKCC. Dr.

Liu’s responsibilities are in

the Molecular Hematopathology Laboratory where

she is appointed Assistant Director. Congratulations

are also in order, as Dr. Liu recently passed her

boards in Molecular Pathology!

Dr. David Pisapia, AssistantProfessor of Pathology

and Laboratory Medicine,

received his medical degree

from Weill Cornell Medical

College in 2009, where he

was AOA and the recipient of

the Herman L. Jacobius Prize

in Pathology. Subsequently,

he joined our Pathology

Residency Training Program and upon completion

of his training accepted a two year Neuropathology

Fellowship at Columbia University. Dr. Pisapia’s

responsibilities lie in the areas of neuropathology

and autopsy pathology and he will work closely

with senior faculty in the Neurology, Neurosurgery

and Neuroscience departments to develop a clinical

research program.

The Department AlsoWelcomes New Faculty ToThe NYP-Lower ManhattanHospital

Dr. Gregory Massimi currently serves as Chief ofPathology and Director of Laboratories at NYP-LMH.

Dr. Massimi received his MD in 1993 from the

University of Rome, Italy and did his anatomic and

clinical pathology residency training from 1993 to

1996 at the University of Massachusetts Medical

Center. Prior to joining us he was a Staff Pathologist

and Laboratory Director at Halifax Regional Health

Systems in South Boston, Virginia.

Dr. Kristina Loukeris received her medical degreein 2005 from the Chicago Medical School, followed

by pathology residency training here in our depart-

ment from July 1, 2005 to June 30, 2009. Sub-

sequently, she served as our Cytopathology Fellow

and then the following year as our Gynecologic

Pathology Fellow. Dr. Loukeris started her position

at New York Downtown Hospital in July 2011.

Dr. Ying Zhang received her MD in 1994 from

Shandong Medical University, China and her PhD in

2002 from Albany Medical College. She did her

anatomic and clinical pathology residency training

from 2006 to 2010, at Rhode Island Hospital.

Following her residency, she did an oncological

pathology fellowship at Memorial Sloan-Kettering

Cancer Center. Since completing her fellowship, she

has been on staff at The Brooklyn Hospital Center,

prior to joining LMH. ■

3

The Department WelcomesSeveral New Faculty

Focusby Daniel M. Knowles, MD

Helen Fernandes, MD

The Department conducted a course, Surgical

Pathology 2013: The Weill Cornell NYC Course, Oct.

10-12, 2013 at the New York Academy of Sciences.

The course was formatted by organ system: Breast

Pathology, Gynecologic Pathology, Hematopathology,

Genitourinary Pathology and Gastrointestinal Path-

ology. The program was a success with participants

spanning the globe from countries including Canada,

Australia, South Korea, Pakistan, The Netherlands, Saudi

Arabia and United Kingdom. Dr. Rhonda K. Yantiss

served as Course Director and Dr. Syed A. Hoda

served as Associate Course Director. The speakers

were comprised of all Weill Cornell faculty. Special

guest speaker, Dr. Christopher P. Crum, Professor,

Harvard Medical School, presented as well. ■

Syed A. Hoda, MD and Rhonda K. Yantiss, MD

Surgical PathologyNYC Course 2013

(left to right) Drs. Zhang, Massimi and Loukeris

Yen-Chun Liu, MD

David Pisapia, MD


◗ Dr. Yashpal Agrawal has been selected to Chairthe College of American Pathologist’s Toxicology

Resource Committee from 2014 onwards. The com-

mittee’s charge is to define and monitor the art and

emerging technologies in toxicology and therapeutic

drug monitoring and to develop effective proficiency

testing and laboratory accreditation programs.

◗ Drs. Domenick J. Falcone and K.M. Faisal Khanattended the annual meeting of the American

Association of Experimental Pathology in Boston,

MA (April, 2013), and presented two posters:

Interleukin-6 induced matrix metalloproteinase-9

expression in macrophages: Cyclooxygenase-2-

dependent and independent pathways (P. Kothari, R.

Pestana, R. Mesaroua, R. Elchaki and D. J. Falcone) and

EP4 antagonist suppresses MMP-9 expression in

aortas derived from apoE-null mice (K.M.F. Khan, and

D.J. Falcone). Dr. Falcone continues to serve as Chair

of the Core of the Basic Sciences Curriculum Comm-

ittee, and was appointed to the Dean’s Curriculum

Design Leadership Group. In May, he was awarded

the Siegel Family Faculty Award at graduation.

◗ In 2013, Dr. David Hajjar was named a SeniorFellow for the 2013-2014 academic year in the

Strategic Policy/Diplomacy Program at the Belfer

Center for Science and International Affairs at

Harvard-Kennedy School of Government, Harvard

University, Cambridge, Mass. The focus of his work

will be aimed at issues related to higher education in

the Middle East. This year, he was awarded industrial

and foundation support to continue his research on

the vascular system from Kowa Pharmaceutical

Corporation, Tokyo, Japan in the amount of

$100,000; and, from the Julia and Seymour Gross

Foundation in the amount of $45,000.

◗ Dr. Tim Hla served as president of The New YorkLipid and Vascular Biology Research Club, and

organized the October meeting on “Sphingolipid

Signaling in Biology and Medicine” (The Rockefeller

University). Dr. Hla has been invited to many

domestic and international academic centers to

present his labs’ studies on the roles of S1P1 and

HuR RNA binding protein in vascular development

and disease, the contributions of sphingolipids and

their receptors to tumor growth, and S1P1 receptor

signaling in a mouse model of multiple sclerosis.

These include Columbia University College of

Physicians and Surgeons (March 20), Uppsala

University, Sweden (April 4), Karolinska Institute,

Stockholm, Sweden (April 5), University of

Pennsylvania, Department of Pharmacology (April

22, 2013), University of Connecticut Health Center,

Farmington, CT (April 29), Yale University/NAVBO

meeting on Lymphatics, New Haven, CT (May 3-4),

Medical University of South Carolina, Charleston, SC

(May 8-10), University of California San Diego,

Department of Pharmacology, CA (May 27-29),

Inserm Paris, Cardiovascular Research Center,

Pompedou Hospital, Paris, France. (June 27), Harvard

University School of Medicine, Vascular Biology

Lectures (Oct 2-3), University of Tokyo, Global

Health Research Institute, Tokyo, Japan (July 31),

FASEB summer research conference on Lysophos-

pholipids, Sapporo, Japan (Aug 3-9), Juntendo

University, Lipid research lecture, Tokyo, Japan (Aug

1), American Heart Association, 2013 Annual meet-

ing, Dallas, TX, USA (Nov 19-20), and NAVBO Annual

Meeting 2013, Cape Cod, MA (October 20-24).

◗ Dr. Cynthia M. Magro was one of the senior

lecturers at the annual Scottsdale course in

Dermatopathology in Scottsdale, Arizona directed

by Dr. Artur Zembowicz. She gave her annual CME

course with Concord Dermatology in North Carolina.

In addition, Dr. Magro delivered the Founder’s

Seminar in Portland, Oregon encompassing four

hours of lectures at the annual Oral and

Maxillofacial Pathology. Her talks encompassed

immunofluorescence, lymphoproliferative disease

and vasculitis. She joined her colleagues Dr. Martin

C. Mihm and Dr. Neil Crowson for their annual

course held in Fort Lauderdale, Florida on

Contemporary Diagnostic Strategies in Dermato-

pathology. Dr. Magro participated in the American

Society of Dermatopathology meeting held in

Washington, delivering a comprehensive review on

the application of immunofluorescence of the

diagnostic agent adjunct in cutaneous dermato-

pathology. Dr. Magro has recently signed a new

contract with Wiley for the second addition of her

book Cutaneous Lymphoid Proliferation. The

second edition of The Melanocytic Proliferation: A

Comprehensive Textbook of Pigmented Lesions

that she has co-authored with Dr. Neil Crowson and

Dr. Martin C. Mihm is currently in press and set for

an early 2014 publication date.

◗ Dr. Juan Miguel Mosquera was appointed as

editorial board member of Archives of Pathology &

Laboratory Medicine, as Section Editor in Precision

Medicine. Dr. Mosquera was an invited speaker

at the Prostate Cancer Foundation Pathology

Workshop for Neuroendocrine Prostate Cancer in

New York City, where he presented emerging data

related to AURKA and MYCN amplifications in this

lethal subtype of prostate cancer. Dr. Mosquera pre-

sented the lectures on Genitourinary Pathology along

with Dr. Brian D. Robinson at the Surgical Pathology2013 Weill Cornell NYC Course on October 10-12.

The course was directed by Drs. Rhonda K.Yantiss and Syed A. Hoda. Drs. Mosquera andCristina Antonescu (MSKCC) presented Recurrent

NCOA2 gene rearrangements in congenital/

infantile spindle cell rhabdomyosarcoma and

Novel MIR143-NOTCH fusions in benign and malig-

nant glomus tumors at the 2013 Annual Meeting

of the United States and Canadian Academy of

Pathology (USCAP), held in March of this year in

Baltimore, MD. These recent discoveries are part

of an established collaboration between Drs.Mosquera, Andrea Sboner and Mark A. Rubinwith Dr. Cristina Antonescu, and have been

recently published.

◗ Dr. Attilio Orazi, Vice-Chair for Hematopathologywas a Visiting Professor in the Department of

Pathology & Laboratory Medicine at North Shore/

Long Island Jewish Hospital, on January 8, 2013.

Later in the same month, in his capacity as an EXCO

member, he attended the business meeting of the

European Association for Hematopathology held in

Istanbul, Turkey. Also in January 2013, Dr. Orazi

presented lectures on Myelodysplastic Syndromes

and Myelodysplastic/Myeloproliferative Neoplasms

at the Tutorial on Neoplastic Hematopathology

directed by Dr. Daniel Knowles (Dr. Orazi is

Associate Course Director of the Tutorial) which was

held in Miami, Florida. In addition, Dr. Orazi chaired

one of the sessions and gave the concluding

remarks. In March 17-23, 2012, Dr. Orazi partici-

pated in the 102th Annual Meeting of the United

States and Canadian Academy of Pathology

(USCAP) held at the Baltimore Convention Center,

March 2-8 in Baltimore, MD. He attended the

annual meetings of the editorial boards upon which

he serves. He authored/co-authored eleven USCAP

presentations (seven platforms and four posters).

Together with Dr. D. Arber (Stanford University), Dr.

Orazi continued to direct the short course entitled

Modern Approach to the Diagnosis of Neoplastic

Splenic Disorders. In April 2013, Dr. Orazi partici-

pated as panelist to the slide review conference

held at MD Anderson Cancer Center, Houston TX,

organized in preparation for the Society for

Hematopathology Workshop which was held in

the same location late in the year. The same month

he participated as panelist to the slide review

conference held in Munich, Germany in prepara-

tion of the 11th International Course of the

European Bone Marrow Working Group (EBMWG)

held later in the year. continued on page 5

Keynotesby Domenick J. Falcone, PhD


5

◗ Dr. Attilio Orazi, continuedIn May 2013, Dr. Orazi was a Visiting Professor at

the Department of Pathology & Laboratory

Medicine, Thomas Jefferson University in

Philadelphia, PA where he presented the annual

Resident Award Lecture and received the Resident

Award. In May at the Hotel Dieu Hospital in Paris,

France, he co-chaired the International Project of

the European Leukemia Network on Myelofibrosis

(MF). The project which is aimed at defining pathol-

ogy response criteria post-targeted therapy in

patients with MF, consisted of a panel slide review

and a consensus conference. Also in May, he

attended the Scientific and Business Meeting of the

EBMWG held in Warsaw, Poland. He delivered two

scientific presentations and chaired the business

meeting. In June, Dr. Orazi co-chaired a clinic-

pathologic conference part of the International

Project of the European Leukemia Network on

Myelofibrosis that was held in Stockholm, Sweden

during the 18th Annual Meeting of the European

Association of Hematology. During the meeting, he

also participated as invited speaker to the program

Updates on Hematology. At the beginning of

September he participated as session chair and

presenter to the 11th Workshop on Bone Marrow

Pathology held in Munich, Germany organized by

the University of Munich. Later the same month, he

attended the Third Meeting of the Bone Marrow

Pathology Group, at the University of Albuquerque,

Albuquerque, NM (September 20, 2013). In October,

he chaired a session and gave a lecture entitled

Bone Marrow Biopsy in Myeloproliferative Neo-

plasms: Usefulness and Limitations at Surgical

Pathology 2013: The Weill Cornell NYC Course,

which was held at The New York Academy of

Science - October 10-12, 2013. Later in the month,

he chaired a session and delivered a lecture at

the 2013 Workshop Society for Hematopathology/

European Association for Haematopathology

entitled Progress in Acute Myeloid Leukemia,

Myelodysplastic Syndromes and Acute Lympho-

blastic Leukemia: Classification and Molecular

Pathogenesis. Dr. Orazi co-authored seven accept-

ed presentations (four platforms and three sum-

maries). Currently, Dr. Orazi is the chairperson of

the European Bone Marrow Working Group; his term

will end in 2014. In May 2013, Dr. Orazi has

organized and directed a successful President

Symposium on Soft Tissue Sarcomas on behalf of

the New York Pathological Society of which is past-

president. Dr. Orazi continues to serve as the

Pathology Chair for all the clinical trials of the

Myeloproliferative Disorders Consortium (chaired

by Ronald Hoffman, MD; Mount Sinai School of

Medicine). For the fifth year in a row, Dr. Orazi has

made the list of “Superdoctors” as well as “Best

Doctors” published by the New York Magazine. He

is also named in Castle Connolly's America's Top

Doctors for Cancer, Top Doctors: New York Metro

Area, and America's Top Doctors.

◗ Dr. Mark A. Rubin is the recipient of the first

Prostate Cancer Center 2013 Mentor of Excellence

Award. He received the award at the 20th Annual

PCF Scientific Retreat in National Harbor, Maryland.

◗ Dr. Maria Shevchuk is the first and organizing

chair of the In Vivo Microscopy Work Group formed

by the CAP in 12/12. This IVM Work Group seeks to

promote awareness and facilitate involvement in

In Vivo Microscopy by pathologists. To this end, Dr.

Shevchuk and members of the Work Group have

contributed to a chapter to the recent CAP eBook;

conducted 2 webinars, with more planned; and will

have multiples presentations at the CAP13 meeting

in Orlando in October 2013. Dr. Shevchuk will also

be presenting IVM and Surgical Pathologists at the

Second Annual Digital Pathology Conference in San

Francisco in February, 2014. Dr. Shevchuk present-

ed 2 abstracts on In Vivo Microscopy at the

International Academy of Pathology meeting in

Cape Town, South Africa in October, 2012, as well

as 3 abstracts at the USCAP meeting in March,

2012 in Baltimore on IVM and on Mismatch gene

abnormalities in prostate cancer. Additional honors

were the featuring of published papers on journal

covers of the Journal of Urology (8/12) and of

Cancer Prevention Research (10/12). Her artwork

was also presented at the 22nd (10/12-1/13) and

the 23rd (10/13-1/14) Weill Cornell Medical

Complex Art Shows.

◗ Dr. Rhonda K. Yantiss was elected President ofthe Rodger C. Haggitt Gastrointestinal Pathology

Society. She delivered lectures at the 2013

Intestinal Immune Based Inflammatory Diseases

Symposium and 2013 Update in Gastroenterology,

Hepatology, & Nutrition Post-Graduate Course, both

of which were sponsored by Columbia University

College of Physicians & Surgeons and Weill Cornell

Medical College. She was also invited to partic-

ipate in an international Pseudomyxoma Peritonei

Consensus Meeting sponsored by the Pelican

Cancer Center in Basingstoke, UK to discuss classi-

fication and diagnosis of pseudomyxoma and

appendiceal neoplasia. Dr. Yantiss was invited to

deliver several international lectures, including

those at the 12th Annual OESO World Congress at

UNESCO Headquarters in Paris, France and the

Collaborative USCAP/German IAP Divisions

Meeting in Cologne, Germany. She was a guest

lecturer at the Memorial Sloan-Kettering Cancer

Center post-graduate course on the Pathology of

Neoplastic Diseases, The Johns Hopkins 13th

Annual Current Topics in Gastrointestinal and Liver

Pathology course, and the Hospital de la Santa

Creu I Sant Pau Surgical Pathology of Neoplastic

Diseases 14th Course, Barcelona, Spain. Dr. Yantiss

directed two post-graduated courses in 2013,

namely Surgical Pathology 2013: The Weill Cornell

NYC Course held at the New York Academy of

Sciences in New York City and the Tutorial on

Pathology of the GI Tract, Pancreas, and Liver at

the Four Seasons Hotel in Miami, Florida. Dr. Yantiss

continues to serve as an ad hoc reviewer for fifteen

journals, member of the editorial boards of the

Archives of Pathology and Laboratory Medicine,

Modern Pathology, American Journal of Clinical

Pathology, and The American Journal of Surgical

Pathology, and Associate Editor of Archives of

Pathology and Laboratory Medicine. She is an

abstract reviewer for the College of American

Pathologists. She serves on the Education

Committee and the Ramzi Cotran Young Investigator

Award Committee of the United States and

Canadian Academy of Pathology. Dr. Yantiss also

wrote several manuscripts and published a text-

book entitled “Advances in Surgical Pathology:

Colorectal Carcinoma and Tumors of the Vermiform

Appendix.” Dr. Yantiss is a member of the

Continuing Medical Education committee and

Center for Advanced Digestive Care at Weill Cornell

Medical College. She directs the gastrointestinal

and liver pathology fellowship and serves as Chief

of the Gastrointestinal Pathology Service at Weill

Cornell Medical College. ■

Keynotescontinued

Award photo from the PCF with Phil Kantoff (2nd fromleft), Elizabeth Platz (middle) and Mark A. Rubin (2ndfrom right) from Dana Farber Cancer Institute/Harvardand Johns Hopkins.



Travel itineraries from our renowned pathology faculty

Dr. Ethel Cesarman organized the 16thInternational Workshop on Kaposi's

sarcoma herpesvirus and related

agents, which was held in Puerto

Vallarta, Mexico in the summer of 2013.

Some of the participants joined a

post-meeting visit to Mexico City, and

are seen here at the top of the moon

pyramid in Teotihuaca.

(top) Dr. Attilio Orazi (front row 2nd from right) traveled to Paris

to attend the European Leukemia

Net Consensus Meeting for therapy

response in primary myelofibrosis,

in May 2013.

(bottom) Dr. Orazi also traveled to Istanbul, Turkey January 2013 to

attend the EAHP EXCO meeting.

Pictured is the Bosphorus with the

Old City in the background.

(top) Dr. Tim Hla visited National Centerfor Global Health and Medicine at the

University of Tokyo in Tokyo, Japan

and delivered a seminar.

(middle) Dr. Hla was invited as a guestlecturer in the Karolinska Institutet,

Stockholm, Sweden and visited the

Nobel Museum.

(bottom) Dr. Hla also attended the 2013 FASEB summer research

conference on Lysophospholipids

and the city of Stockholm.

Many of our faculty are internationallyrecognized for their accomplishments.Consequently, they are frequently invited to institutions around the worldto present their research and also to receive awards for their clinical and scientific contributions. Here is a sampling of some of the recent international activities of some of our Pathology faculty.

Pathology Faculty’s Global Travels

7

In Sapporo, Japan at the foothills of Mount Yotei, the second most famous Mountain in Japan on the island of Hokkaido. Photo: Dr. Tim Hla.

Dr. Dong Seok Jeon, President

of the Korean Society of Laboratory

Medicine, presented Dr. HannaRennert with a Plaque of Appreciation for her lecture entitled

“Molecular Applications in Oncology

Testing” given at the 54th Annual

Meeting of the Korean Society for

Laboratory Medicine which was

held in Daegu, Korea, on October

24-25th, 2013.

Dr. Audrey Schuetz traveled to Nazarbayev University,

located in Astana, Kazakhstan,

to teach laboratory medicine

to pre-medical students. The

photo shows the Microbiology

Laboratory, where she taught

the students about culture plates

and testing bacteria for antibiotic

resistant bacteria. Dr. Schuetz

says “the experience was

challenging and interesting.

Other than the language barrier,

which was only occasionally

an issue, the students were

engaged and so eager to learn.

As always, it was fascinating

learning about their culture and

working with them as a guest in

their country. Of course, the food

was quite different, especially the

various cuts and preparations of

the horse meat I was eagerly

invited to partake in when

I stepped off the plane!”

Dr. Mark A. Rubin traveledto Shoal Bay, NSW, Australia

to attend the EpiGenetics

2013 meeting. Pictured is

a view of Shoal Bay.

Dr. Surya Seshan(3rd from left) traveled

to New Delhi, India in

September 2013, where

she lectured at the

All India Institute of

Medical Sciences.

Resident's Corner



Welcome to Our New Residents

Mustafa Namir Al-Kawaaz,MD / PGY-1 Dr. Al-Kawaaz graduated inApril 2013 from Weill CornellMedical College in Qatar aftercompleting pre-medical under-graduate studies at the sameinstitution.

Jordan Arkin, MD / PGY-1 Dr. Arkin graduated in May2013 from Indiana UniversitySchool of Medicine (AOA).She received her BS degreein Ecology & EvolutionaryBiology, Cell & MolecularBiology from Tulane Univ-ersity in May 2009.

Esther Cheng, DO / PGY-1 Dr. Cheng graduated in May2013 from New York Collegeof Osteopathic Medicine ofNY Institute of Technology.She received her BS degreein Biological Sciences fromFordham University in 2008.

Isabelle Cui, MD / PGY-1 Dr. Cui graduated in May2013 from the University ofMaryland School of Medicine.She received her BA degreein Public Health & ArtHistory from Johns HopkinsUniversity in 2009.

Robert DeSimone, MD / PGY-1

Dr. DeSimone graduated inMay 2013 from Stony BrookUniversity School of Medicine(AOA). He received his BSdegree in Biological Sciencesfrom Cornell University in2009.

Michael Nowak, MD / PGY-1Dr. Nowak graduated in April2013 from the University atBuffalo School of Medicineand Biomedical Sciences. Hereceived his BS degree inBiotechnology and MedicalTechnology from the Univ-ersity of Buffalo in 2009.

4th Annual Resident’s Research DayThe 4th Annual Resident’s Research Day was held on April 11, 2013 atthe Griffis Faculty Club. Overall there were 10-oral presentations withthree winners: Drs. Kaplan, Park and Turner. The judges were: Drs. SuryaSeshan, Ehud Lavi, Wayne Tam and Mikhail Roshal. The following arethe winning presentations:

t Rachel Kaplan, MD “Sentinel LymphNode Biopsy is a Reliable Method forLymph Node Evaluation in NeoadjuvantChemotherapy Treated Breast CancerPatients”

Kyung Park, MD u

“ERG Gene Translocation PredictsProgression of High Grade Prostatic

Intraepithelial Neoplasia to Prostate Cancer”

t Kevin Turner, MD, PhD“An ERG/SPINK1 Double Stain for ProstateNeedle Core Biopsies with High Grade PIN”

Francesca Khan, MD u“Winning photo of polydactyly from the digital photo contest”

Housestaff EventsIn October, the faculty and housestaff enjoyed an evening of teambuilding at the Lucky Strike Entertainment party space at 12th Avenuein NYC. The evening consisted of bowling, ping-pong and billiards.Everyone had a great time.

9

Welcome to Our New Fellows

Ronnie Abraham, MD Dermatopathology Dr. Abraham graduated in2009 from Jefferson MedicalCollege. He completed hisAP/CP training at the Hospitalof the University of Penn-sylvania in June 2013.

Constantin Friedman, MD,PhD Genitourinary PathologyDr. Friedman graduated in2010 from the Mount SinaiSchool of Medicine. He com-pleted his AP training atNYPH/WCMC in June 2013.

Ping Gong, MD, PhD Hematopathology Dr. Gong graduated in 2000with her MD from NanjingUniversity, China and subse-quently received her PhD in2007 from the University ofMaryland. From May 2007to June 2009, she was a

Postdoctoral Research Fellow at the University ofMaryland and then joined their AP/CP trainingprogram, which she completed in June 2013.

Melanie Hawver, MDGynecologic PathologyDr. Hawver graduated in 2008from SUNY Upstate MedicalUniversity. She completed herAP/CP training from 2008to 2012, at Columbia Univer-sity followed by a SurgicalPathology Fellowship at the

Hospital of the University of Pennsylvania whichconcluded in June 2013.

Maija Kluru, MD, PhD Dermatopathology Dr. Kluru graduated in 2005with her MD/PhD from theUniversity of Helsinki. Shewas a postdoctoral researchfellow from May 2005 to June2008, in the Department ofGenetic Medicine hat WCMC.

From June 2008 – July 2009, she was an intern ingeneral surgery at NYPH/WCMC. In August 2009,she became a postdoctoral research fellow in the

Department of Dermatology at Columbia Universityand in July 2010 joined the Dermatology ResidencyTraining Program at NYPH/WCMC, which shecompleted in June 2013.

David Molina, MD Cytopathology Dr. Molina graduated in 2005from the University Autono-mous of Guadalajara followedby a one-year Fifth Pathwayprogram through New YorkMedical College. In 2007, hewas a postdoctoral fellow

at New York Medical College in the Department ofPathology and then in July of 2008, he joined theAP/CP residency training program at St. Vincent’sMedical Center, before joining the program at St.Luke’s-Roosevelt Hospital, where he completedhis training in June 2012. He was a SurgicalPathology fellow at Memorial Sloan-KetteringCancer Center from 2012 to 2013 which concludedin June 2013.

Ugur Ozerdem, MDBreast PathologyDr. Ozerdem graduated in1993 from Hacettepe Univ-ersity School of Medicine,Turkey and completed anOphthalmology Residency atthe same institution, from1993 to 1997. From 1998

to 2000, he was a fellow at the University ofCalifornia, San Diego, California Shiley Eye Centerand then from 2000 to 2003, an American HeartAssociate fellow at the Sanford-Burnham MedicalResearch Institute in La Jolla, California. From 2003to 2008, he was an Assistant Professor at theLa Jolla Institute for Molecular Medicine, beforebeing appointed as an Associate Professor at the LaJolla Bioengineering Institute. In July 2009, hejoined the AP/CP residency program at LoyolaUniversity Medical Center and completed histraining in June 2013.

Kathryn Piotti, MDGastrointestinal PathologyDr. Piotti graduated in 2009from the University ofMedicine and Dentistry ofNew Jersey. She completedher AP/CP training at NYPH/WCMC which concluded inJune 2013.

Emily Storch, MD Transfusion Medicine Dr. Storch graduated in 2008from the University ofPittsburgh School of Med-icine. She completed aninternship year in InternalMedicine at Yale University,followed by a year of research

at the same institution. She completed CP trainingat the University of Buffalo in June 2013.

Andrew Turk, MD Molecular GeneticsDr. Turk graduated in 2008from Columbia College ofPhysicians and Surgeons andthen joined their AP/CP resi-dency training program. In2012, he became a SurgicalPathology fellow at the same

institution and completed his training in June 2013.

Justin Wells, MDBreast PathologyDr. Wells graduated in 2005,from the Uniformed ServicesUniversity of Health Sciencesin Bethesda, MD. He complet-ed his AP/CP residency train-ing from 2005 to 2009, at theNational Capitol Consortium

(Combined Walter Reed Army Medical Center andNational Naval Medical Center) in Washington, DC.From 2009 onward, he has held a number ofpositions within the Armed Services. Prior to joiningour program, he was the Director of SurgicalPathology at Walter Reed National Military MedicalCenter.

Jing Zhou, MD, PhDHematopathologyDr. Zhou graduated in 1996from Beijing Medical Univer-sity, China and subsequently,received her PhD in 2002from Drexel University. From2002 to 2007, she was aPostdoctoral Research Fellow

at The Wistar Institute in Philadelphia, and wasappointed as a Staff Scientist from 2007 to 2009.She then completed her AP/CP training at theHospital of the University of Pennsylvania whichconcluded in June 2013.

Visit our Residency Program on Facebook: www.facebook.com/cornellpatholresidencypgm

Mancuso M, Jiang L, Cesarman E, Erickson D: Multiplexedcolorimetric detection of Kaposi's sarcoma associatedherpesvirus and Bartonella DNA using gold and silvernanoparticles. Nanoscale 5:1678-86, 2013.

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH,Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ,Ratner L, Cesarman E, Tulpule A: Pegylated liposomal dox-orubicin, rituximab, cyclophosphamide, vincristine, andprednisone in AIDS-related lymphoma: AIDS MalignancyConsortium Study 047. J Clin Oncol 31:58-64, 2013.

Byun M, Ma CS, Akçay A, Pedergnana V, Palendira U,Myoung J, Avery DT, Liu Y, Abhyankar A, Lorenzo L, SchmidtM, Lim HK, Cassar O, Migaud M, Rozenberg F, Canpolat N,Aydogan G, Fleckenstein B, Bustamante J, Picard C,Gessain A, Jouanguy E, Cesarman E, Olivier M, Gros P, AbelL, Croft M, Tangye SG, Casanova JL: Inherited human OX40deficiency underlying classic Kaposi sarcoma of childhood.J Exp Med 210:1743-59, 2013.

Wong LY, Brulois K, Toth Z, Inn KS, Lee SH, O'Brien K, LeeH, Gao SJ, Cesarman E, Ensser A, Jung JU: The product ofKSHV K4.2 regulates immunoglobulin secretion and calci-um homeostasis by interacting with and inhibiting pERP1.J Virol 87:12069-79, 2013.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, RodinaA, Taldone T , Erdjument-Bromage H, Chomet M, BlasbergR, Melnick A, Cerchietti L, Chiosis G, Wang YL, CesarmanE: Targeting the Hsp90-associated viral oncoproteomein gammaherpesvirus-associated malignancies. Blood122:2837-47, 2013.

Damania B, Cesarman E: Chapter 65: Kaposi’s sarcoma-associated herpesvirus. In: Fields Virology. 6th Edition.Knipe DM and Howley PH (Eds). Lippincott Williams &Wilkins. 2080-2128, 2013.

Giulino-Roth L, Cesarman E: Molecular biology of Burkittlymphoma. In: Burkitt’s Lymphoma. Robertson ES (Ed).Springer, New York, 2013.

Said J, Cesarman E, Knowles DM: Lymphadenopathy andthe lymphoid neoplasms associated with HIV infection andother causes of immunosuppression. In: Knowles’Neoplastic Hematopathology. 3rd Ed. Orazi A, Weiss L,Foucar K, Knowles DM (Eds). Lippincott Williams andWilkins, Philadelphia, 2013.

Wang, YL, Cesarman E, Knowles DM: Antigen receptorgenes: Structure, function, and molecular analysis in clini-cal applications. In: Knowles’ Neoplastic Hematopathology.3rd Ed Orazi A, Weiss L, Foucar K, Knowles DM (Eds).Lippincott Williams and Wilkins, Philadelphia, 2013.

Cesarman E: Pathology of lymphoma in HIV. Curr OpinionOncol 25:487-494, 2013.

Cesarman E: Gammaherpesvirus and lymphoproliferativedisorders. Annual review of pathology: Mechanisms ofdisease, Vol. 9, 2013 [ePub ahead of print].

Geyer JT, Niesvizky R, Jayabalan DS, Mathew S,Subramaniyam S, Geyer AI, Orazi A, Ely SA: IgG4 plasmacell myeloma: new insights into the pathogenesis of IgG4-related disease. Mod Pathol doi: 10.1038/mod-pathol.2013.159. [Epub ahead of print], 2013.

Xiong Y, Lee HJ, Mariko B, Lu YC, Dannenberg AJ, Haka AS,Maxfield FR, Camerer E, Proia RL, Hla T: Sphingosinekinases are not required for inflammatory responses inmacrophages. J Biol Chem Sep 30. [Epub ahead of print]PubMed PMID: 24081141, 2013.

Garris CS, Wu L, Acharya S, Arac A, Blaho VA, Huang Y,Moon BS, Axtell RC, Ho PP, Steinberg GK, Lewis DB, SobelRA, Han DK, Steinman L, Snyder MP, Hla T, Han MH:Defective sphingosine 1-phosphate receptor 1 (S1P1)phosphorylation exacerbates TH17-mediated autoimmuneneuroinflammation. Nat Immunol 14:1166-72. doi:10.1038/ni.2730. PubMed PMID: 24076635, 2013.

Li MH, Hla T, Ferrer F: FTY720 inhibits tumor growth andenhances the tumor-suppressive effect of topotecanin neuroblastoma by interfering with the sphingolipidsignaling pathway. Pediatr Blood Cancer 60:1418-23. doi:10.1002/pbc.24564. PubMed PMID: 23704073; PubMedCentral PMCID: PMC3751174, 2013.

Howe LR, Subbaramaiah K, Kent CV, Zhou XK, Chang SH,Hla T, Jakobsson PJ, Hudis CA, Dannenberg AJ: Geneticdeletion of microsomal prostaglandin E synthase-1 sup-presses mouse mammary tumor growth and angiogenesis.Prostaglandins Other Lipid Mediat 2013 Apr 25. doi:pii:S1098-8823(13)00026-9. 10.1016/j.prostaglandins. PubMed PMID: 23624019, 2013.

Montrose DC, Scherl EJ, Bosworth BP, Zhou XK, Jung B,Dannenberg AJ, Hla T: S1P₁ localizes to the colonicvasculature in ulcerative colitis and maintains bloodvessel integrity. J Lipid Res 54:843-51. doi: 10.1194/jlr.M034108. PubMed PMID: 23296878; PubMed CentralPMCID: PMC 3617958, 2013.

Deeb RS, T Nuriel, C Cheng, B Summers, BD Lamon, SSGross and DP Hajjar: Characterization of a cellular deni-trase activity that reverses nitration of cyclooxygenase inthe vessel wall. Am J Physiol 305: H687-698, 2013.

Jiang M, Zhang L, Ma X,Chen Y, Li X, Zhu Y, Hajjar DP, DuanY, Han J: Tamoxifen inhibits macrophage fatty acid bindingprotein (FABP4) expression by a glucocorticoid receptorand PPAR combinational pathway. Biochem J 454: 467-477, 2013.

Hajjar DP, Gotto AM Jr: Biological relevance of inflamma-tion and oxidative stress in the pathogenesis of arterialdiseases. Am J Pathol 182: 1474-1481, 2013.

Hajjar DP, Gotto AM Jr: Launching of an american medicalschool in the middle east: Educational challenges in a multi-cultural environment. Internat J Higher Educ 2: 67-75, 2013.

Magro CM, Wang X, Subramaniyam S, Darras N, Mathew S:Cutaneous double-hit B-Cell lymphoma: An aggressive Formof B-Cell lymphoma with a propensity for cutaneous dissem-ination.Am J Dermatopathol 2013 Jul 31. [Epub ahead of print]

Magro CM, Wang X, Subramaniyam S, Darras N, MathewS: Cutaneous double-hit B-Cell lymphoma: An aggressiveform of B-Cell lymphoma with a propensity for cutaneousdissemination. Am J Dermatopathol Jul 31, 2013.

Magro CM, Iwenofu H, Nuovo GJ: Paraneoplastic sclero-derma-like tissue reactions in the setting of an underlyingplasma cell dyscrasia: a report of 10 cases. Am JDermatopathol 35:561-8, 2013.

Shendrik I, Crowson AN, Magro CM: Follicular cutaneoussquamous cell carcinoma: an under-recognized neoplasmarising from hair appendage structures. Br J Dermatol169:384-8, 2013.

Gulati CM, Satlin MJ, Magro CM, Kirou KA: Two systemiclupus erythematosus patients with severe pleurisy: similarpresentations, different causes. Arthritis Care Res(Hoboken) 65:1005-13, 2013.

Magro CM, Wang X: Cocaine-associated retiform purpura: ac5b-9-mediated microangiopathy syndrome associated withenhanced apoptosis and high levels of intercellular adhesionmolecule-1 expression. Am J Dermatopathol 35:722-30, 2013.

Magro CM, Wang X: CCL5 expression in panniculitic T-celldyscrasias and its potential role in adipocyte tropism. Am JDermatopathol 35:332-7, 2103.

Magro CM, Yang A, Fraga G: Blastic marginal zone lymphoma:a clinical and pathological study of 8 cases and review ofthe literature. Am J Dermatopathol 35:319-26, 2013.

Plaza JA, Feldman AL, Magro C: Cutaneous CD30-positivelymphoproliferative disorders with CD8 expression: a clini-copathologic study of 21 cases. J Cutan Pathol 40:236-47,2013. Sagransky MJ, Deng AC, Magro CM: Primary cutaneouslangerhans cell sarcoma: a report of four cases and reviewof the literature. Am J Dermatopathol 35:196-204, 2013.

Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T,Barouk-Fox S, Knowles DM, Orazi A: Morphologic andcytogenetic differences between post-polycythemic

myelofibrosis and primary myelofibrosisin fibrotic stage. Mod Pathol doi:10.1038/modpathol. 2013. 109. [Epubahead of print] Jun 21, 2013.

Robinson DR, Wu YM, Kalyana-Sundaram S,Cao X, Lonigro R, Sung YS, Chen CL, ZhangL, Wang R, Su F, Iyer M, Roychowdhury S, Siddiqui J, PientaK, Kunju LP, Talpaz M, Mosquera JM, Singer S, SchuetzeS, Antonescu CR, Chinnaiyan AM: Identification of recurrentNAB2-STAT6 gene fusions in solitary fibrous tumor byintegrative sequencing. Nature Gen 45:180-5, 2013.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD,Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, NelsonJB, Nanus DM, Rubin MA: Concurrent AURKA and MYCNgene amplifications are harbingers of lethal treatment-relatedneuroendocrine prostate cancer. Neoplasia 15:1-10, 2013.

Mosquera JM, Sboner A, Zhang L, Chen LC, Sung YS,Chen HW, Agaram NP, Briskin D, Basha B, Singer S, RubinMA, Tuschl T, Antonescu CR: Novel miR143-NOTCH fusionsin benign and malignant glomus tumors. GenesChromosom Cancer [Epub ahead of print], 2013.

Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, PeturNielsen G, Mino-Kenudson M, Huang HY, Mosquera JM,Dei Tos PA, Fletcher CDM: Dedifferentiation in gastroin-testinal stromal tumor to an anaplastic KIT negative phe-notype – a diagnostic pitfall. Morphologic and molecularcharacterization of 8 cases occurring either de-novo orafter Imatinib therapy. Am J Surg Pathol 37:385-92, 2013.

Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A,Steiner E, Horninger W, Bektic J, Ladurner-Rennau M,Rubin MA, Demichelis F, Klocker H: Distinct ERGrearrangement prevalence in prostate cancer: higher fre-quency in young age and in low PSA prostate cancer.Prostate Cancer Prostatic Dis 16:132-8, 2013.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, DowningSR, He J, Schnall-Levin M, White J, Sanford EM, An P, SunJ, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E,Zhao M, Balasubramanian S, Terzic S, Richards T, BanningV, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H,Mosquera JM, Rubin MA, et al: Development and valida-tion of a clinical cancer genomic profiling test based onmassively parallel DNA sequencing. Nat Biotechnol Oct 20[Epub ahead of print], 2013.

Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A,Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, VanAllen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, NickersonE, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G,Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL,Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, ArdlieK, Kantoff PW, Berger MF, Gabriel SB, Golub TR, MeyersonM, Lander ES, Elemento O, Getz G, Demichelis F*, RubinMA*, Garraway LA*: Punctuated evolution of prostate cancergenomes. Cell 153:666-77, 2013. *Joint Senior Author

The Cancer Genome Atlas Research Network; Analysisworking group: Baylor College of Medicine, Creighton CJ,Morgan M, Gunaratne PH, Weill Cornell Medical College,Mosquera JM, Rubin MA: National Human GenomeResearch Institute, Guyer MS, Ozenberger BA, Sofia HJ:Comprehensive molecular characterization of clear cellrenal cell carcinoma. Nature 499:43-9, 2013.

Antonescu CR, Le Loarer F, Mosquera JM, Sboner A,Zhang L, Chen LC, Chen HW, Pathan N, Krausz T, DicksonBC, Weinreb I, Rubin MA, Hameed M, Fletcher CDM: NovelYAP1-TFE3 fusion defines a distinct subset of epithelioidhemangioendothelioma. Genes Chromosom Cancer 52:775-84, 2013.

Antonescu CR, Zhang L, Shao SY, Mosquera JM, WeinrebI, Katabi N, Fletcher CDM: Frequent PLAG1 gene rearrange-ments in skin and soft tissue myoepithelioma with ductaldifferentiation. Genes Chromosom Cancer 52:675-82,2013.

Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C,Carskadon S, Siddiqui J, Park K, Miguel Mosquera J,Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N:Novel dual-color immunohistochemical methods fordetecting ERG-PTEN and ERG-SPINK1 status in prostatecarcinoma. Mod Pathol 26:835-48, 2013.



Faculty Publications in 2013

11

Mosquera JM, Sboner A, Zhang L, Kitabayashi N, ChenLC, Sung YS, Wexler LH, LaQuaglia MP, Edelman M,Sreekantaiah, Rubin MA, Antonescu CR: Recurrent NCOA2gene rearrangements in congenital/infantile spindle cellrhabdomyosarcoma. Genes Chromosom Cancer 52:538-50, 2013.

Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM,Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H,Melnick AM, Elemento O, Demichelis F, Rubin MA:Epigenetic repression of miR-31 disrupts androgen recep-tor homeostasis and contributes to prostate cancer pro-gression. Cancer Res 73:1232-44, 2013.

Strauss KA, DuBiner L, Simon M, Zaragoza M, Sengupta PP,Li P, Narula N, Dreike S, Platt J, Procaccio V, Ortiz-GonzálezXR, Puffenberger EG, Kelley RI, Morton DH, Narula J,Wallace DC: Severity of cardiomyopathy associated withadenine nucleotide translocator-1 deficiency correlateswith mtDNA haplogroup. Proc Natl Acad Sci USA110:3453-8, 2013.

Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J,Muzikan-sky A, Fathi AT, de Leval L, Orazi A, HasserjianRP: Clinicopath-ologic analysis of acute myeloid leukemiaarising from chronic myelomonocytic leukemia. ModPathol 26:751-61, June 2013.

Hu S, Xu-Monette ZY, Balasubramanyam A, ManyamGC, Visco C, Tzankov A, Liu WM,Miranda RN, Zhang L,Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y,Bhagat G, Richards KL, et al: CD30 expression defines anovel subgroup of diffuse large B-cell lymphoma withfavorable prognosis and distinct gene expression signa-ture: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121:2715-24,2013.

Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D,Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, BhagatG, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q,Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, et al: Singlenucleotide variation in the TP53 3' untranslated region indiffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4529-40, 2013.

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L,Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN,Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, BhagatG, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH,Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, et al:MYC/BCL2 protein coexpression contributes to the inferiorsurvival of activated B-cell subtype of diffuse large B-celllymphoma and demonstrates high-risk gene expressionsignatures: a report from The International DLBCLRituximab-CHOP Consortium Program. Blood 121:4021-31, 2013.

Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K,Orazi A, Bhagat G, His ED, van Krieken JH, Ponzoni M, GoRS, Piris MA, Møller MB, Young KH, Tzankov A: Addition ofrituximab to chemotherapy overcomes the negative prog-nostic impact of cyclin E expression in diffuse large B-celllymphoma. J Clin Pathol [Epub ahead of print], Jun 17,2013.

Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE,Harrison C, Hoffman R: Advances in myelofibrosis: a clini-cal case approach. Haematologica 98:1499-509, 2013.

Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ:Evaluation of WHO criteria for diagnosis of polycythemiavera: a prospective analysis. Blood 122:1881-6, 2013.

Zhang Y, Shin SJ, Liu D, Ivanova E, Foerster F, Ying H,Zheng H, Xiao Y, Chen Z, Protopopov A, Depinho R, Paik JH:ZNF365 promotes stability of fragile sites and telomeres.Cancer Discov PMID: 23776040, 2013.

Zhang Y, Park E, Kim C, Paik JH: ZNF365 promotes stalled

replication forks recovery to maintain genome stability. CellCycle Aug 6;12(17). PMID: 23966166, 2013.

Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC,Paik JH: FoxO3 coordinates metabolic pathways to main-tain redox balance in neural stem cells. EMBO J [Epubahead of print] PubMed PMID: 24013118, 2013.

Panarelli NC, Schreiner AM, Brandt SM, Shepherd NA,Yantiss RK: Histologic features and cytologic techniquesthat aid pathologic stage assessment of colonic adenocar-cinoma. Am J Surg Pathol 37:1252-1258, 2013.

Park JS, Kim YT, Lee A, Lee Y; EPI-HPV-030 Study Group,Jenkins D, Pirog EC, Molijn AC, Ramakrishnan G, Chen J:Prevalence and type distribution of Human Papillomavirusin cervical adenocarcinoma in Korean women. GynecolOncol 130:115-20, 2013.

Quint KD, de Koning MN, Quint WG, Pirog EC: Progressionof cervical low grade squamous intraepithelial lesions: insearch of prognostic biomarkers. Eur J Obstet GynecolReprod Biol 2115: 319-9, 2013.

Renwick N, Cekan P, Masry PA, McGeary SE, Miller JB,Hafner M, Li, Z, Mihailovic A, et al: Multicolor microRNAFISH effectively differentiates tumor types. JCI 123:2694-2702, 2013.

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF,Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N,Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA,Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G,Theodorescu D, James CD, Czerniak B, Miettinen M,Waldman T: Frequent truncating mutations of STAG2 inbladder cancer. Nat Genet Oct 13 [Epub ahead of print],2013.

Park K, Chiu YL, Rubin MA, Demichelis F, Mosquera JM:ERG/TFF3/HMWCK triple immunostain: A novel tissue-based biomarker in prostate cancer with potential clinicalapplication. Human Pathol 44:2282-92, 2013.

Beltran H, Rubin MA: New strategies in prostate cancer:translating genomics into the clinic. Clin Cancer Res19:517-23, 2013.

Poptsova M, Banerjee S, Gokcumen O, Rubin MA,Demichelis F: Impact of constitutional copy number vari-ants on biological pathway evolution. BMC Evol Biol 13:19,2013.

Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA,Zimmermann M, Bond R, Shou J, Li C, Blattner M, LonardDM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'MalleyBW, Mitsiades N: Prostate cancer-associated mutations inspeckle-type POZ protein (SPOP) regulate steroid receptorcoactivator 3 protein turnover. Proc Natl Acad Sci U S A110:6997-7002, 2013.

Park K, Chiu YL, Rubin MA, Demichelis F, Mosquera JM:V-ets erythroblastosis virus E26 oncogene homolog(avian)/Trefoil factor 3/high-molecular-weight cytokeratintriple immunostain: a novel tissue-based biomarker inprostate cancer with potential clinical application. HumPathol 44:2282-92, 2013.

Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH,Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA,Adam RM, Oesterreich S, Di Vizio D, Freeman MR: Scaffoldattachment factor B1 regulates the androgen receptor inconcert with the growth inhibitory kinase MST1 and themethyltransferase EZH2. Oncogene Jul 29 [Epub ahead ofprint], 2013.

Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, LappalainenT, Sboner A, Lochovsky L, Chen J, Harmanci A, Das J,Abyzov A, Balasubramanian S, Beal K, Chakravarty D,Challis D, Chen Y, Clarke D, Clarke L, Cunningham F, EvaniUS, Flicek P, Fragoza R, Garrison E, Gibbs R, Gumuş ZH,Herrero J, Kitabayashi N, Kong Y, Lage K, Liluashvili V,Lipkin S, MacArthur DG, Marth G, Muzny D, Pers TH, RitchieGRS, Rosenfeld JA, Sisu C, Wei X, Wilson M, Xue Y, Yu F,1000 Genomes Project Consortium, Dermitzakis ET, YuH, Rubin MA, Tyler-Smith C, Gerstein M, AbecasisGR, Auton A, Brooks LD, DePristo MA, Durbin RM,Handsaker RE, McVean GA: Integrative annotation of vari-ants from 1092 humans: application to cancer genomics.

Science 342:1235587, 2013.

Xu X, Hussain WM, Vijai J, Offit K, RubinMA, Demichelis F, Klein RJ: Variants at IRX4as prostate cancer expression quantitativetrait loci. Eur J Hum Genet Sep 11 [Epubahead of print], 2013.

Barbieri CE, Rubin MA: Molecular characterization ofprostate cancer following androgen deprivation: the devilin the details. Eur Urol Aug 30 [Epub ahead of print], 2013.

Menon R, Deng M, Rüenauver K, Queisser A, Offermann A,Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G,Wernert N, Oberbeckmann N, Biskup S, Rubin MA,Shaikhibrahim Z, Perner S: Somatic copy number alter-ations by whole exome sequencing implicates YWHAZ andPTK2 in castration-resistant prostate cancer. J Pathol Sept23 [Epub ahead of print], 2013.

Rubin MA, Dhar R, Diringer MN: Racial differences in with-drawal of mechanical ventilation do not alter mortality inneurologically injured patients. J Crit Care Oct 8 [Epubahead of print], 2013.

Jacobs SE, Soave R, Shore TB, Satlin MJ, Schuetz AN,Magro C, Jenkins SG, Walsh TJ: Human rhinovirus infec-tions of the lower respiratory tract in hematopoietic stemcell transplant recipients. Transpl Infect Dis 15:474-86,2013.

Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, SeshanSV, Pardee JD, Szeto HH: The mitochondrial-targeted com-pound SS-31 re-energizes ischemic mitochondria by inter-acting with cardiolipin. J Am Soc Nephrol 24:1250-61,2013.

Fu L, Wang G, Shevchuk M, Nanus D, Gudas L: Expressionof mutated constitutively active HIF2a in mouse kidneyproximal tubule cells causes abnormal glycogen depositionbut no tumorigenesis. Cancer Res PMID 23447580, 2013.

Tewari AK, Ali A, Metgud S, Theckumparampil N, SrivastavaA, Khani F, Shevchuk MM, Durand M, Sooriakumaran P, LiJ, Leung R, Peyser A, Gruschow S, Asija V, Harneja N:Functional outcomes following robotic prostatectomyusing athermal, traction free risk-stratified grades of nervesparing. World J Urol PMID 23354288, 2013.

Kim SY, Jeong S, Chah KH, Jung E, Baek KH, Kim ST, ShimJH, Chun E, Lee KY: Salt-inducible kinase 1 and 3 nega-tively regulate toll-like receptor 4 -mediated signal. MolEndocrinol PMID: 24061540, September 23, 2013.

Greenblatt MB, Shim JH: OsteoImmunology: A briefintroduction. Immune Netw 13:111-115, PMID: 24009537,2013.

Shim JH, Greenblatt MB, Zou W, Huang Z, Wein MN, BradyN, Hu D, Charron J, Brodkin HR, Petsko GA, Zaller D, ZhaiB, Gygi S, Glimcher LH, Jones DC: Schnurri-3 regulatesERK downstream of WNT signaling in osteoblasts. J ClinInvest 123:4010-22 PMID: 23945236, 2013.

Greenblatt MB, Shim JH, Glimcher LH: Mitogen-activatedprotein kinase pathways in osteoblasts. Ann Rev Cell DevBiol 29:2.1-2.17 PMID: 23725048, 2013.

Park TY, Kim SH, Shin YC, Lee NH, Lee CRK, Shim JH,Glimcher LH, Mook-Jung I, Cheong E, Kim WK, Lim JS, LeeSK: Amelioration of neurodegenerative diseases by celldeath-induced cytoplasmic delivery of humanin. J ControlRelease 166:307-315 PMID: 23298615, 2013.

Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C,McDonough PL, Jiang Z, DuPont HL, Garneau P, Harel J,Rishniw M, Simpson KW: Multidrug resistance is commonin Escherichia coli associated with ileal Crohn’s disease.Inflamm Bowel Dis 19:141-150, 2013.

Hudacko R, Zhou XK, Yantiss RK: Immunohistochemicalstains for CD3 and CD8 do not improve detection of gluten-sensitive enteropathy in duodenal biopsies. Mod Pathol 26:1241-1245, 2013.

Sagaert X, Tousseyn T, Yantiss RK: Gastrointestinal B-celllymphomas: From understanding B-cell physiology to clas-sification and molecular pathology. World J GastrointestOncol 4: 238-249, 2012. ■

Faculty Publications continued



5th Annual Papanicolaou Tutorialon Diagnostic CytopathologyuJuly 24-25, 2014Weill Auditorium and Archbold CommonsNew York, New YorkCourse Director: Rana S. Hoda, MD

Targeted AudienceCytopathologists, pathologists, residents and cytotechnologists

Course Goals and Objectives This 2-day program will consist of lectures, case presentations and discussions designed toprovide pathologists with a special interest incytopathology, pathologists-in-training and cyto-technologists with an in-depth discussion of currentcriteria and changing concepts in DiagnosticCytopathology. Diagnostic cytopathology performsa vital role in the evaluation and treatment ofpatients with non-neoplastic and neoplastic disease.This course is needed to advance the specializedknowledge of practicing cytologists and further, toencourage the exploration of current approachesand concepts in classification, differential diagnosisand management. It is designed to provide updatedpractical, problem-solving knowledge and informa-tion for cytopathologists, pathologists, residentsand cytotechnologists.

6th Annual SymposiumTutorial on Pathology of theGI Tract, Pancreas and LiveruNovember 10-14, 2014Walt Disney World and Dolphin ResortOrlando, FloridaCourse Director: Rhonda K. Yantiss, MD

Targeted AudienceGeneral surgical pathologists and pathologists-in-training

Course Goals and Objectives This course is designed to update physicians onadvances in our understanding of gastrointestinaldiseases, address problems faced during thepathologic evaluation of tissue samples, and providepathologists with a framework for interpretation ofboth histologic patterns of disease and results ofmolecular analyses. The program will consist oflectures, case presentations and discussionsdesigned to provide attendees with an in-depthdiscussion of diagnostic problems that arise whenevaluating materials obtained from the gastro-intestinal tract, pancreas, and liver, and informthem regarding the application and interpretationof immunohistochemical and molecular studies inthe diagnosis and classification of these diseases.

2014-2015 CME Conference Calendar

Orlando • November ‘14

Reserve early. Space is limited! CME Information/Registration: Ms. Jessica Misner (212)746-6464 • [email protected]

NYC • July ‘14 Naples • January ‘15

Tutorial on NeoplasticHematopathologyuJanuary 19-23, 2015Waldorf Astoria NaplesNaples, FloridaCourse Director: Daniel M. Knowles, MDAssociate Course Director: Attilio Orazi, MD

Targeted AudiencePathologists, pathologists-in-training and medical oncologists/hematologists

Course Goals and Objectives This 5-day course is designed to update physicians on the latest advances in Neoplastic Hemato-pathology. The program will consist of lectures,case presentations and discussions designed toprovide pathologists, pathologists-in-trainingand medical oncologists/hematologists with anin-depth discussion of diagnostic problems thatarise in neoplastic hematopathology. In additionto discussions of recent advances in the morpho-logic classification of hematopoietic tumors, theapplication and interpretation of immunologicaland cytochemical studies and molecular tech-niques in the diagnosis and classification of thesediseases will be presented.

xSTARR Cancer ConsortiumResearch Grant

Title: Co-clinical trials using organoids for patients with advanced prostate cancerPrincipal Investigator: Mark A. Rubin, MDPeriod of Support: 01/01/14-12/31/15Total Direct Costs: $700,000

xSTARR Cancer ConsortiumResearch Grant

Title: Genome sequencing of outlier responders to systemic cancer therapiesPrincipal Investigator: Mark A. Rubin, MDPeriod of Support: 01/01/14-12/31/15Total Direct Costs: $400,000

xProstate Cancer FoundationChallenge Award

Title: Targeting and mechanistic insights underlyingN-Myc driven Neuroendocrine Prostate CancerPrincipal Investigators: David S. Rickman, PhD and Mark A. Rubin, MDPeriod of Support: 01/01/14-12/31/15Total Direct Costs: $500,000

xUnited States Department of DefenseCareer Development Award

Title: RHAMMB promotes liver-specific metastasis of pancreatic neuroendocrine tumorsPrincipal Investigator: Yi-Chieh Nancy Du, PhDPeriod of Support: 09/15/13-09/14/15Total Direct Costs: $240,000

xV FoundationTranslational Research Grant

Title: Ubiquitin ligase as a novel diagnostic markerand therapeutic target for colorectal cancerPrincipal Investigators: Drs. Pengbo Zhouand Yao-Tseng ChenPeriod of Support: 11/01/13-10/31/16Total Direct Costs: $600,000

xClinical and Translational Science CenterNovel Award

Title: Identification of Ubiquitin Ligase as a Predictive Biomarker for Colorectal Polyps and Early Stages of Colorectal CancerPrincipal Investigator: Pengbo Zhou, PhDPeriod of Support: 12/01/13-05/31/14Total Direct Costs: $12,500

xNew York State Office of Science, Technology and Academic Research (NYSTAR)CAT Grant Award

Title: Topical Therapeutics for Skin Diseases associated with DNA DamagePrincipal Investigator: Pengbo Zhou, PhDPeriod of Support: 07/01/13-06/30/14Total Direct Costs: $49,825 ■

Newly Awarded Grants in Pathology

Volume 20 • February 2014Editor Daniel M. Knowles, MDCo-Editor David P. Hajjar, PhD

Managing Editor Gina L. Imperato, MPADesign JBRH Advertising & Design, Inc.

The Pathologist is an annual publication of the Department of Pathology and Laboratory Medicine

at NewYork-Presbyterian Hospital /Weill Cornell Medical Center.

If you have any comments or questions, please contact:Managing Editor, Gina L. Imperato • tel: (212) 746-6464

e-mail: [email protected]

weill co rnell medical college main interest of his laboratory involves the molecular and biological...

Documents